Highlights Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
10.96 ^USD	-18.48%		-19.55%	+34.87%

05-10	Iovance Biotherapeutics' Patient Selection for Amtagvi Launch Minimizing Attrition, Truist Securities Says	MT
05-10	Iovance Biotherapeutics Shares Fall After Q1 Revenue Misses Estimates	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Iovance Biotherapeutics' Patient Selection for Amtagvi Launch Minimizing Attrition, Truist Securities Says	05-10	MT
Iovance Biotherapeutics Shares Fall After Q1 Revenue Misses Estimates	05-10	MT
Iovance Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Iovance Biotherapeutics Q1 Loss Narrows -- Shares Higher After Hours	05-09	MT
Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Posts Q1 Revenue $715,000	05-09	MT
Iovance Biotherapeutics Syas FDA Lifts Partial Clinical Hold on LN-145	03-04	DJ
Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer	03-04	CI
Iovance Biotherapeutics Q4 Loss Narrows, Posts Revenue	02-29	MT
Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Reports Q4 Revenue $482,000	02-28	MT
Iovance Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-28	CI
Iovance Shares Hits 52-Week High After Offering Pricing, FDA Approvals	02-20	DJ
Dwindling Rate Cut Hopes Push Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	02-20	MT
Iovance Biotherapeutics' Amtagvi for Advanced Melanoma Receives Accelerated FDA Approval	02-16	MT
US FDA grants accelerated approval for Iovance's skin cancer cell therapy	02-16	RE
Iovance Says Amtagvi Gets Accelerated Approval for Advanced Melanoma	02-16	DJ
FDA approves Iovance Biotherapeutics cell therapy for skin cancer	02-16	RE
Iovance Biotherapeutics, Inc.?s AMTAGVI? (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma	02-16	CI
Iovance Biotherapeutics Pauses Lung Cancer Trial Following FDA's Clinical Hold	12-27	MT
Iovance Biotherapeutics Says US FDA Halted Lung Cancer Trial After Participant's Death; Shares Fall Pre-Bell	12-27	MT
Iovance Shares Fall Premarket As FDA Places Study On Hold After Patient Death	12-27	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Highlights

Filters